IsoRay Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth at the world brachytherapy meeting. The program, presented by GEC-ESTRO (The Groupe Européen de Curiethérapie and the European Society for Therapeutic Radiology and Oncology), in co-operation with ABS (American Brachytherapy Society), ALATRO (Asociacion Latinoamericana de Terapia Radiante Oncologica), and the Indian and Australasian brachytherapy groups, will take place May 10-12 in Barcelona, Spain. IsoRay’s introduction to the world brachytherapy community will include a number of activities at the Company's booth. Leading physicians from major medial institutions will host a series of discussion groups regarding the innovative GliaSite® radiation system treatment, which represents a major advance over previous brain cancer treatments. In addition to demonstrating the GliaSite® radiation system, IsoRay's European distributor, Karlheinz Goehl-Medizintechnik Goehl, will be on hand to respond to questions. Booth activities will also feature slide shows, videos, and working demonstrations of the application of mesh with Cesium-131 embedded seeds for use in brain, head and neck, lung, occular, gynecological and prostate cancers. GliaSite® remains the world's only system that allows doctors to place a specified dosage of liquid radiation in areas where cancer is most likely to remain after surgical brain tumor removal. The specificity of the dosage placement means damage is less likely to occur to healthy brain tissue in contrast to other treatments. The liquid radiation balloon catheter device impacts the ability of the tumor to recur which is a vital benefit for patients both in longevity and quality of life. IsoRay has exclusive worldwide distribution rights for the GliaSite® radiation therapy system. According to IsoRay CEO Dwight Babcock, the Company expects to hold a number of high level meetings in response to international inquiries regarding distribution. Babcock noted, "The international medical community has become increasingly aware of the key advantages GliaSite® offers patients battling Glioblastomas and metastasized brain cancers. We expect interest in GliaSite® to continue to increase as doctors adopt this groundbreaking radiation therapy system." Babcock noted that he expects international sales to begin in the near term.